Psoriatic Arthritis: What the Dermatologist Needs to Know, Part 1
نویسندگان
چکیده
منابع مشابه
[Psoriatic arthritis: what the dermatologist needs to know, part 1].
Psoriatic arthritis is defined as inflammatory arthritis occurring in patients with psoriasis and is classified as a seronegative spondyloarthropathy associated with human leukocyte antigen B27. Between 25 and 35% of patients with psoriasis go on to develop psoriatic arthritis during the course of their disease. Given that the skin is affected before the joints in most cases, the dermatologist ...
متن کاملPsoriatic arthritis--what the dermatologist needs to know.
Psoriasis is commonly associated with a co-existent arthritis known as psoriatic arthritis (PsA). Although there is some treatment overlap for psoriasis and psoriatic arthritis, it is possible that dermatologists may not diagnose or treat appropriately patients who are developing psoriatic arthritis at an early stage of the disease process when joint damage may be preventable. In this article w...
متن کاملThe biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know.
INTRODUCTION In this issue of the Annals of the Rheumatic Diseases, Gisondi et al (see page 26) present an ultrasonography study showing that otherwise asymptomatic patients with psoriasis often have evidence for subclinical disease involving the enthesis (ie, the site of insertion of a tendon, ligament or joint capsule to bone). The authors suggest that this may represent a useful approach for...
متن کاملJuvenile idiopathic arthritis - what the clinician needs to know.
Juvenile idiopathic arthritis (JIA) includes several forms of chronic arthritis in childhood with no apparent cause. JIA is the most common rheumatic disease in children, and may result in pain, joint deformity, and growth im- pairment, with possible persistent active arthritis into adulthood. Prior treatment involved non-specific agents, several with significant adverse effects. The recent use...
متن کاملBiopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
The entry of biosimilar forms of biopharmaceutical therapies for the treatment of psoriasis and other immune-mediated disorders has provoked considerable interest. Although dermatologists are accustomed to the use of a wide range of generic topical agents, recognition of key differences between original agent (ie, the name brand) and the generic or biosimilar agent is necessary to support optim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Actas Dermo-Sifiliográficas (English Edition)
سال: 2010
ISSN: 1578-2190
DOI: 10.1016/s1578-2190(10)70680-6